Literature DB >> 26616301

Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent.

Petra Jilma-Stohlawetz1, Peter Quehenberger1, Heinrich Schima2, Martin Stoiber2, Paul Knöbl3, Barbara Steinlechner4, Alessia Felli4, Bernd Jilma5.   

Abstract

INTRODUCTION: The high shear rates induced by left ventricular assist devices cause acquired von Willebrand disease (aVWD). We hypothesised that an ex vivo model could be established to study whether mechanical shear stress alone causes aVWD or whether this process depends also on the VWF cleavage protein ADAMTS-13 and on platelets.
MATERIALS AND METHODS: Healthy volunteers and two patients with congenital ADAMTS-13 deficiency donated blood. In vitro closed extracorporeal circuits were established using medically approved left ventricular assist devices (LVAD). VWF multimers were quantified by gel electrophoresis; VWF antigen, ristocetin cofactor activity (VWF:RCo), ADAMTS-13 levels and platelet function were assessed.
RESULTS: The high shear stress in the extracorporeal circulation rapidly decreased VWF:RCo and thereby the VWF:RCo/VWF:Ag ratio by 47% (p<0.01) to pathologically low values. Concomitantly, high molecular weight multimers (HMWM) decreased: up to 14-15 mers were visible on the gels at baseline, which were reduced by a maximum of 6-7 mers, corresponding to an average 68% lower densitometry signal of HMWM (p<0.001). This was accompanied by marked reduction of aggregation by various agonists (p<0.005). In contrast, the two patients with congenital thrombocytopenic purpura with virtually complete deficiency of ADAMTS-13 activity had only a minimal or no decrease in multimers (p<0.005 vs. healthy controls). Similarly, no or minimal depletion of large multimers occurred, when normal plasma circulated without platelets.
CONCLUSION: An in vitro model for LVAD associated aVWD demonstrated that ADAMTS-13 and platelets contribute to the depletion of HMWM of VWF.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Circulatory support device; LVAD; Platelets

Mesh:

Substances:

Year:  2015        PMID: 26616301     DOI: 10.1016/j.thromres.2015.11.002

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  12 in total

1.  New methodologies to accurately assess circulating active transforming growth factor-β1 levels: implications for evaluating heart failure and the impact of left ventricular assist devices.

Authors:  Donna Mancini; Juan Monteagudo; Mayte Suárez-Fariñas; Jeffrey Bander; Rohan Varshney; Juana Gonzalez; Barry S Coller; Jasimuddin Ahamed
Journal:  Transl Res       Date:  2017-11-05       Impact factor: 7.012

2.  High Molecular Weight von Willebrand Factor Multimer Loss and Bleeding in Patients with Short-Term Mechanical Circulatory Support Devices: A Case Series.

Authors:  Michael Goldfarb; Lawrence S Czer; Lee D Lam; Jaime Moriguchi; Francisco A Arabia; Oksana Volod
Journal:  J Extra Corpor Technol       Date:  2018-06

3.  Early signatures of bleeding and mortality in patients on left ventricular assist device support: novel methods for personalized risk-stratification.

Authors:  Tara Shrout; Travis Sexton; Olga Vsevolozhskaya; Maya Guglin; Alexis Shafii; Susan Smyth
Journal:  Biomarkers       Date:  2019-05-06       Impact factor: 2.658

4.  Effects of HeartWare ventricular assist device on the von Willebrand factor: results of an academic Belgian center.

Authors:  Fatemeh Esmaeilzadeh; Aurélien Wauters; Walter Wijns; Jean-François Argacha; Philippe van de Borne
Journal:  BMC Cardiovasc Disord       Date:  2016-08-02       Impact factor: 2.298

5.  The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin.

Authors:  Katarina D Kovacevic; Nina Buchtele; Christian Schoergenhofer; Ulla Derhaschnig; Georg Gelbenegger; Christine Brostjan; Shuhao Zhu; James C Gilbert; Bernd Jilma
Journal:  Sci Rep       Date:  2020-07-07       Impact factor: 4.379

6.  Functional capillary impairment in patients with ventricular assist devices.

Authors:  Patricia P Wadowski; Barbara Steinlechner; Daniel Zimpfer; Thomas Schlöglhofer; Heinrich Schima; Martin Hülsmann; Irene M Lang; Thomas Gremmel; Renate Koppensteiner; Sonja Zehetmayer; Constantin Weikert; Joseph Pultar; Bernd Jilma
Journal:  Sci Rep       Date:  2019-04-11       Impact factor: 4.379

7.  A Flow Induced Autoimmune Response and Accelerated Senescence of Red Blood Cells in Cardiovascular Devices.

Authors:  James P Buerck; Dustin K Burke; David W Schmidtke; Trevor A Snyder; Dimitrios Papavassiliou; Edgar A O'Rear
Journal:  Sci Rep       Date:  2019-12-19       Impact factor: 4.379

8.  Development of malignancies and their outcomes in patients supported on continuous-flow left ventricular assist devices-a systematic review.

Authors:  Elizabeth J Maynes; Jonathan S Gordon; Matthew P Weber; Thomas J O'Malley; Tyler M Bauer; Chelsey T Wood; Rohinton J Morris; Louis E Samuels; John W Entwistle; H Todd Massey; Vakhtang Tchantchaleishvili
Journal:  Ann Cardiothorac Surg       Date:  2021-05

9.  Coagulopathy and its associated factors among patients with a bleeding diathesis at the University of Gondar Specialized Referral Hospital, Northwest Ethiopia.

Authors:  Melak Aynalem; Elias Shiferaw; Yemataw Gelaw; Bamlaku Enawgaw
Journal:  Thromb J       Date:  2021-06-01

Review 10.  A reappraisal of the pharmacologic management of gastrointestinal bleeding in patients with continuous flow left ventricular assist devices.

Authors:  Audrey J Littlefield; Gregory Jones; Alana M Ciolek; Melana Yuzefpolskaya; Douglas L Jennings
Journal:  Heart Fail Rev       Date:  2020-09-01       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.